Gregory Renza
Stock Analyst at RBC Capital
(2.09)
# 2,771
Out of 4,712 analysts
208
Total ratings
34.86%
Success rate
-4.76%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Reiterates: Outperform | $68 | $21.71 | +213.22% | 3 | Dec 23, 2024 | |
| CRMD CorMedix | Maintains: Outperform | $11 → $12 | $8.33 | +44.06% | 5 | Dec 19, 2024 | |
| MNKD MannKind | Upgrades: Outperform | $7 → $10 | $6.74 | +48.37% | 1 | Dec 19, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $44 → $47 | $19.31 | +143.40% | 11 | Dec 17, 2024 | |
| CDTX Cidara Therapeutics | Initiates: Outperform | $34 | $23.43 | +45.11% | 1 | Dec 13, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Outperform | $179 | $123.73 | +44.67% | 12 | Dec 12, 2024 | |
| SPRB Spruce Biosciences | Reiterates: Sector Perform | $2 → $1.5 | $0.40 | +279.27% | 13 | Dec 11, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $55 → $57 | $34.19 | +66.72% | 6 | Dec 10, 2024 | |
| CGON CG Oncology | Reiterates: Outperform | $66 | $28.30 | +133.22% | 2 | Dec 6, 2024 | |
| AMGN Amgen | Maintains: Outperform | $360 → $330 | $264.49 | +24.77% | 15 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $16 | $3.25 | +392.31% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $6 | $1.83 | +227.87% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $2 | $0.25 | +700.00% | 8 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $4.55 | -12.09% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $15 → $16 | $19.47 | -17.82% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.82 | +112.77% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.69 | +191.59% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $35 | $14.69 | +138.26% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $33.82 | +0.53% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.90 | +233.33% | 8 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $26 | $19.57 | +32.86% | 10 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $24.29 | +39.98% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $25.30 | +141.11% | 11 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.42 | +367.84% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $26 | $17.07 | +52.31% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.01 | +298.01% | 11 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $18 | $0.25 | +7,100.00% | 7 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $8.81 | +1,943.13% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $3.14 | +2,447.77% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.74 | +1,624.14% | 3 | Jun 2, 2020 |
Jasper Therapeutics
Dec 23, 2024
Reiterates: Outperform
Price Target: $68
Current: $21.71
Upside: +213.22%
CorMedix
Dec 19, 2024
Maintains: Outperform
Price Target: $11 → $12
Current: $8.33
Upside: +44.06%
MannKind
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $6.74
Upside: +48.37%
Viridian Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $19.31
Upside: +143.40%
Cidara Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $34
Current: $23.43
Upside: +45.11%
Jazz Pharmaceuticals
Dec 12, 2024
Reiterates: Outperform
Price Target: $179
Current: $123.73
Upside: +44.67%
Spruce Biosciences
Dec 11, 2024
Reiterates: Sector Perform
Price Target: $2 → $1.5
Current: $0.40
Upside: +279.27%
Agios Pharmaceuticals
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $34.19
Upside: +66.72%
CG Oncology
Dec 6, 2024
Reiterates: Outperform
Price Target: $66
Current: $28.30
Upside: +133.22%
Amgen
Nov 27, 2024
Maintains: Outperform
Price Target: $360 → $330
Current: $264.49
Upside: +24.77%
Nov 25, 2024
Maintains: Outperform
Price Target: $25 → $16
Current: $3.25
Upside: +392.31%
Nov 15, 2024
Maintains: Sector Perform
Price Target: $7 → $6
Current: $1.83
Upside: +227.87%
Nov 14, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $0.25
Upside: +700.00%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $4.55
Upside: -12.09%
Nov 7, 2024
Maintains: Sector Perform
Price Target: $15 → $16
Current: $19.47
Upside: -17.82%
Nov 7, 2024
Maintains: Outperform
Price Target: $5 → $6
Current: $2.82
Upside: +112.77%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.69
Upside: +191.59%
Nov 1, 2024
Reiterates: Outperform
Price Target: $35
Current: $14.69
Upside: +138.26%
Oct 30, 2024
Reiterates: Outperform
Price Target: $34
Current: $33.82
Upside: +0.53%
Oct 18, 2024
Reiterates: Outperform
Price Target: $13
Current: $3.90
Upside: +233.33%
Oct 14, 2024
Maintains: Outperform
Price Target: $27 → $26
Current: $19.57
Upside: +32.86%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $24.29
Upside: +39.98%
Sep 24, 2024
Reiterates: Outperform
Price Target: $61
Current: $25.30
Upside: +141.11%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.42
Upside: +367.84%
Aug 7, 2024
Maintains: Outperform
Price Target: $29 → $26
Current: $17.07
Upside: +52.31%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.01
Upside: +298.01%
Nov 10, 2023
Maintains: Outperform
Price Target: $23 → $18
Current: $0.25
Upside: +7,100.00%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $8.81
Upside: +1,943.13%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $3.14
Upside: +2,447.77%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.74
Upside: +1,624.14%